for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Sumitomo Chemical Co Ltd

4005.T

Latest Trade

507.00JPY

Change

-1.00(-0.20%)

Volume

7,885,800

Today's Range

506.00

 - 

518.00

52 Week Range

443.00

 - 

633.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
508.00
Open
515.00
Volume
7,885,800
3M AVG Volume
144.91
Today's High
518.00
Today's Low
506.00
52 Week High
633.00
52 Week Low
443.00
Shares Out (MIL)
1,635.01
Market Cap (MIL)
840,966.70
Forward P/E
9.03
Dividend (Yield %)
4.33

Next Event

Q2 2020 Sumitomo Chemical Co Ltd Earnings Release

Latest Developments

More

Nufarm Announces Sale Of Nufarm South America To Sumitomo For $1,188 Million

Nufarm Announces Placement Of $97.5 Mln Preference Securities To Sumitomo Chemical Co

Sumitomo Chemical Co Ltd - Appoints New Chairman And New President

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Sumitomo Chemical Co Ltd

SUMITOMO CHEMICAL COMPANY, LIMITED has five business segments. The Petrochemicals segment is mainly engaged in the manufacture and sale of inorganic and organic chemicals, synthetic fiber materials, petrochemical, synthetic resin, metal acrylate and others. The Energy and Functional Materials segment is engaged in the manufacture and sale of alumina products, aluminum, additives, dye, synthetic rubbers engineering plastics and battery parts, among others. The IT-related Chemicals segment is engaged in the manufacture and sale of optical goods, color filters, semiconductors processing materials, and touch sensor panels and others. The Pharmaceuticals segment is engaged in the provision of medical products and radioactive diagnostic products, among others.

Industry

Chemical Manufacturing

Contact Info

Tokyo Sumitomo Twin Bldg. (East)

2-27-1, Shinkawa

+81.3.55435500

https://www.sumitomo-chem.co.jp/

Executive Leadership

Masakazu Tokura

Chairman of the Board, Representative Director

Keiichi Iwata

President, Executive President, Representative Director

Toshihisa Deguchi

Executive Vice President, Representative Director

Hiroshi Niinuma

Senior Managing Executive Officer, Director

Rei Nishimoto

Senior Managing Executive Officer, Chairman of Subsidiaries, Representative Director

Key Stats

2.57 mean rating - 14 analysts
Sell
Hold
Buy
Revenue (MM, JPY)

2017

2.0K

2018

2.2K

2019

2.3K

2020(E)

2.3K
EPS (JPY)

2017

52.310

2018

81.810

2019

72.170

2020(E)

56.263
Price To Earnings (TTM)
8.11
Price To Sales (TTM)
0.36
Price To Book (MRQ)
0.86
Price To Cash Flow (TTM)
3.35
Total Debt To Equity (MRQ)
98.48
LT Debt To Equity (MRQ)
60.10
Return on Investment (TTM)
7.39
Return on Equity (TTM)
4.12

Latest News

Latest News

Australia's Nufarm to sell some South America assets to Sumitomo for $805 mln

Australian crop protection company Nufarm Ltd on Monday said it will divest its crop protection and seed treatment assets in South America to Japan's Sumitomo Chemical Co Ltd for A$1.19 billion ($804.80 million).

UPDATE 1-Australia's Nufarm cuts 2019 outlook, turns to Japan's Sumitomo for cash

Australian crop protection company Nufarm Ltd on Thursday cut its fiscal 2019 earnings guidance and said it would raise about A$97.5 million ($66.8 million) through a share placement with Japan's Sumitomo Chemical Co Ltd .

BRIEF-Sumitomo Chemical Halts Production Of Material Used In LED At JV With Samsung Electronics - Nikkei

* SUMITOMO CHEMICAL HAS HALTED PRODUCTION OF A MATERIAL USED IN LED AT A JV WITH SAMSUNG ELECTRONICS - NIKKEI Source text: Further company coverage:

BRIEF-Kayac to buy system for 70 mln yen

* Says it will buy a system for 70 million yen from SuMiKa Co.,Ltd., effective Sept. 19

BRIEF-Sumitomo Chemical buys Kyowa Hakko's agrochemical segment - Nikkei

* Sumitomo Chemical Co Ltd to buy Kyowa Hakko Kirin's agrochemical segment in deal valued at 6 billion yen to 7 billion yen

BRIEF- Sumitomo Chemical unit Sumitomo Dainippon Pharma announces unblinding of phase 3 study of Napabucasin

* Says its unit Sumitomo Dainippon Pharma Co Ltd announced today that the company decided to unblind the BRIGHTER study, a phase 3 global study in patients with gastric and gastro-esophageal junction (GEJ) cancer of napabucasin, an investigational cancer stemness inhibitor...

BRIEF-Sumitomo Chemical to buy out its JV with Trinseo - Nikkei

* Sumitomo Chemical to buy out its joint venture with America's Trinseo for tens of millions of dollars - Nikkei Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up